Beta Lactamases: A Weapon Against Antibiotics
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Bacterial Pathogens".
Deadline for manuscript submissions: 15 December 2024 | Viewed by 108
Special Issue Editor
Special Issue Information
Dear Colleagues，
Beta lactamases are products of bacteria important for various health science disciplines. They have been widely used in nature because they are basic and common biologic survival mechanisms of bacteria used to fight against the biologic products of other living organisms. In particular, for clinical medicine, beta lactamases have considerable significance because they represent a basic mechanism employed by bacteria against the action of antibiotics; from this point of view, beta lactamases are real bacterial weapons used against antibiotics. This leads to bacterial antimicrobial resistance that has been recognized as a major threat for public health in all countries, and it has had considerable global consequences in regards to the morbidity and mortality of patients. Fortunately, modern pharmacology and clinical therapeutics have led to the discovery of the clinical practice of several new combinations of beta lactam antibiotics with beta lactamase inhibitors, as well as basic and clinical research advances. These combination drugs provide pragmatic therapeutic solutions in clinical medicine in cases of a considerable subset of patients exhibiting infections due to bacteria that produce beta lactamases that may inactivate beta lactam antibiotics when administered alone (without the beta lactamase inhibitor).
Dr. Matthew E. Falagas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- beta lactamases
- bacteria
- antibiotics
- antimicrobial resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
